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Pociej-Marciak, W.; Chrząszcz, M.;
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Abstract: Background: The pathogenesis of central serous chorioretinopathy (CSC) remains a sub-
ject of intensive research. We aimed to determine correlations between plasma levels of selected
angiogenic factors and different forms of CSC. Methods: Eighty patients were enrolled in the study
including 30 with a chronic form of CSC, 30 with acute CSC, and 20 controls. Presence of active
CSC was determined by fluorescein angiography (FA), indocyanine green angiography (ICGA), and
swept-source optical coherence tomography (SS-OCT). Plasma concentrations of angiopoietin-1,
endostatin, fibroblast growth factor, placental growth factor (PlGF), platelet-derived growth factor
(PDGF-AA), thrombospondin-2, vascular endothelial growth factor (VEGF), VEGF-D, and pigment
epithelium–derived factor were measured, and the results were compared between groups. Addition-
ally, mean choroidal thickness (CT) was measured in all patients. Results: Levels of angiopoietin-1
(p = 0.008), PlGF (p = 0.045), and PDGF-AA (p = 0.033) differed significantly between the three
groups. Compared with the controls, VEGF (p = 0.024), PlGF (p = 0.013), and PDGF-AA (p = 0.012)
were downregulated in the whole CSC group, specifically PDGF-AA (p = 0.002) in acute CSC and
angiopoietin-1 (p = 0.007) in chronic CSC. An inverse correlation between mean CT and VEGF levels
was noted in CSC patients (rho = −0.27, p = 0.044). Conclusions: Downregulated angiopoietin-1,
VEGF, PDGF-AA, and PlGF levels may highlight the previously unknown role of the imbalanced
levels of proangiogenic and antiangiogenic factors in the pathogenesis of CSC. Moreover, down-
regulated VEGF levels may suggest that choroidal neovascularization in CSC is associated with
arteriogenesis rather than angiogenesis.
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1. Introduction
Central serous chorioretinopathy (CSC) is a common disease that belongs to the
pachychoroid-related disorders, characterized by serous retinal detachment, which is
associated with a local leakage from the thicker choroid through impaired retinal pigment
epithelium (RPE) [1]. For a long time, a simple classification of CSC into acute and chronic
forms has been used; however, it was based solely on the duration of serous neurosensory
retinal detachment [2]. Nowadays, as new pathogenic concepts of CSC emerge and modern
multimodal imaging becomes available, various new classifications are being developed,
but so far, none of them has fully reflected the complexity of this clinical entity [3,4].
Daruich et al. classified CSC as acute, non-resolving, recurrent, chronic, or inactive, which
more precisely refers to the course of the disease [5].
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As the pathogenesis and pathophysiology of CSC have not been fully explained,
the available treatment modalities are suboptimal, especially in long-standing cases [2,6].
Growing evidence indicates that the pathomechanism of CSC is associated with dysfunc-
tion of the thickened choroid (an important risk factor), with subsequent impairment of
the RPE [1,7]. Some authors have also postulated that downregulation of the cell–cell adhe-
sion molecules in the vascular endothelium could increase the permeability of choroidal
vessels, causing fluid leakage under the neurosensory retina [8,9]. In the present study,
we attempted to find an association between these phenomena in CSC and the levels of
proangiogenic and antiangiogenic factors in human plasma.
Although the role of elevated levels of vascular endothelial growth factor (VEGF) and
other cytokines in the pathogenesis of the pachychoroid disease has been speculated on in
some papers, they more often referred to other forms of this disease entity than CSC [10,11].
Recent studies suggested that eyes with CSC may be at higher risk of age-related mac-
ular degeneration (AMD) or one of its subtypes (polypoidal choroidal vasculopathy or
pachychoroid neovasculopathy), or that the development of CSC and AMD/polypoidal
choroidal vasculopathy may share a common background [12–14]. Data on systemic
changes in the expression of proangiogenic and antiangiogenic factors and their role in
choroidal vascular homeostasis associated with CSC are scarce. Apart from our previous
research, we identified only one report evaluating the plasma level of VEGF in patients
with CSC [15,16].
It is well-known that CSC may be complicated by choroidal neovascularization (CNV),
a typical feature for neovascular AMD (nAMD). The prevalence of this complication was
reported to range from 15.6% to 25% [16,17]. Extensive research of AMD included the
levels of proangiogenic factors [18–20]. Impaired expression of antiangiogenic factors was
shown to play an important role in the development of CNV in the course of nAMD [21].
By analogy, some of these etiological factors typical for nAMD could also be involved in
the course of different forms of pachychoroid disease such as CSC. Interestingly, whereas
acute exposure to some angiogenic factors such as VEGF results in fast but self-limited hy-
perpermeability of normal vessels, chronic exposure leads to profound changes in venular
function and structure, which results in its chronic hyperpermeability and pathological
vessel formation [22]. Angiogenesis and arteriogenesis play a crucial role in tissue develop-
ment, repair, and regeneration, but also in ocular pathology [23]. Both processes depend
on the intricate balance of angiogenic and inflammatory factors [24,25].
To our knowledge, no studies have reported alterations in the levels of circulating
angiogenic factors in patients with CSC, which is not an angiogenic condition in itself,
but since it is a pachychoroid disease, its phenotype is characterized by attenuation of
the choriocapillaris overlying dilated choroidal veins [7]. The purpose of our study was
to highlight the previously unknown role of the imbalanced levels of proangiogenic and
antiangiogenic factors in CSC. Additionally, our findings may support the search for new
therapeutic strategies in CSC and provide new targets for development in the field.
2. Materials and Methods
This case-control study included 60 white adult patients (11 women and 49 men)
diagnosed with CSC in the Department of Ophthalmology and Ocular Oncology in Kraków,
Poland, between November 2017 and June 2018. The control group comprised 20 healthy
volunteers from the University Hospital in Kraków, who were matched for sex, age,
smoking status, and hypertension. The diagnosis of CSC was based on characteristic
findings of indirect ophthalmoscopy, fluorescein angiography (FA), indocyanine green
angiography (ICGA, SPECTRALIS, Heidelberg Engineering, Heidelberg, Germany), and SS-
OCT (DRI OCT Atlantis, Topcon, Japan). Ocular exclusion criteria were as follows: nAMD,
uveitis, diabetic retinopathy, vasculitis, polypoidal choroidal vasculopathy, neovascular
glaucoma, anti-VEGF treatment, and other diseases causing macular exudation. Systemic
exclusion criteria included any malignancy, acute illness, rheumatoid arthritis, psoriasis,
renal or hepatic dysfunction, acute myocardial infarction or stroke within the preceding six
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months, and corticosteroid treatment. The study was approved by Jagiellonian University
Bioethical Committee (Approval No. 122.6120.266.2016), and all patients and controls
provided written informed consent to participate in the study.
2.1. Clinical Examination
The measurement of best-corrected visual acuity, indirect ophthalmoscopy of the
fundus, and SS-OCT were performed in all groups, whereas FA and ICGA were per-
formed only in the CSC group. Central serous chorioretinopathy was classified as acute
when symptoms and clinical signs lasted less than six months, whereas chronic CSC was
diagnosed when symptoms lasted six months or longer.
The diagnosis of CSC was based on the SS-OCT, FA, and ICGA findings. For SS-OCT,
the criteria included current or previous pigment epithelium detachment and/or serous
retinal detachment as well as increased CT. On FA, symptoms characteristic for CSC were
sought such as focal or multispot dye leakage, dye pooling, or widespread areas of granular
hyperfluorescence. Finally, for ICGA, remarkable findings included areas of persistent
hyperpermeability during the early and middle phases as well as central hyperfluorescence
during the late phase.
Choroidal thickness was assessed using the method previously described by
Branchini et al. [26]. Mean CT was considered as the average of the measurements from
three points, which were localized beneath the fovea as well as 750 µm temporally and
750 µm nasally from the fovea. The measurements were done by two experienced ophthal-
mologists (AKT and IKB).
2.2. Sample Collection
Blood was drawn from the antecubital vein into BD Vacutainer (BD Life Sciences,
Franklin Lakes, NJ, USA) from all participants. Tubes contained (EDTA) as an antico-
agulant for plasma preparation. The plasma levels of 10 different angiogenic proteins
were measured using the Human Angiogenesis A Premixed Mag Luminex Performance
Assay (FCSTM02-10, R&D Systems, Minneapolis, MI, USA). This multiplex immunoas-
say contains premixed fluorogenic beads with monoclonal antibodies against angiogenin,
angiopoietin-1, endostatin, FGF-acidic, FGF-basic, PlGF, PDGF-AA, thrombospondin-2,
VEGF, and VEGF-D. The measurements were done according to the manufacturer’s proto-
col using 1:4 diluted plasma and the xMAP analyzer (Luminex Corporation, Austin, TX,
USA). Bead-trapped cytokines were detected by biotin-streptavidin sandwich immuno-
complex fluorescence. The results were calculated using 7-point standard curves and
proprietary software, Milliplex Analyst Version 5.1 (Merck, Darmstadt, Germany). The
plasma levels of angiogenin exceeded the highest concentration of the standard curve
calibrator (29,900 pg/mL) in 94% of the samples; therefore, they were not included in
further analysis.
2.3. Statistical Analysis
Qualitative data were presented as counts and percentages. Quantitative data were
shown as means and standard deviations (SD) for normally distributed variables and as
medians (Me) and interquartile ranges (IQRs) otherwise. The normality of quantitative
variables was tested using the Kolmogorov–Smirnov test. Intergroup comparisons of
qualitative variables were made using the Pearson 2 test; this test was used when expected
frequencies in more than 80% of cells were higher than five; and the Fisher–Freeman–
Halton test was used otherwise. Intergroup comparisons of quantitative variables were
made using the 1-way analysis of variance (ANOVA) for normally distributed variables and
the Kruskal–Wallis test for variables with nonnormal distribution. When the comparison
of the three groups yielded a significant p value, a pairwise comparison with Bonferroni
correction was used. For FGF-acidic, the ANOVA was used after removing one outlier
case present in the acute-CSC group. The CSC (both chronic and acute) and control groups
were compared using the t-test or Mann–Whitney test, as appropriate. The results of the
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comparison were presented graphically with a box plot, where the line inside the box
represents a median; the lower and upper sides of the box represent the lower and upper
quartiles, respectively; the horizontal lines connected to the box with vertical lines represent
cases distant up to 1.5 of the IQR from the respective quartiles; circles represent cases distant
from 1.5 to 3 IQRs from the respective quartile; and asterisks represent cases distant by
more than 3 IQRs from the respective quartile. The strength of the relationship between
quantitative variables was estimated using the Spearman rank correlation coefficient. A p
value of less than 0.05 was considered significant. The analysis was performed with IBM
SPSS Statistics 24 for Windows statistical package.
3. Results
In the group with acute CSC (n = 30), 83.3% of patients were male compared with
80.0% in the group with chronic CSC (n = 30) and 55% in the control group (n = 20). The
mean (SD) age was 42.7 (9.9) years for patients with acute CSC, 44.5 (6.1) years for those
with chronic CSC, and 39.2 (7.4) years for the controls. The demographic and clinical
characteristics of the groups are presented in Table 1. Patients with CSC and controls
did not differ with regard to age, sex, smoking status, and the prevalence of systemic
hypertension. Among the 11 women with CSC, three were after menopause and two used
hormonal contraception. Angiotensin-converting enzyme inhibitors were used by four
patients with acute CSC, two patients with chronic CSC, and three controls; β-blockers, by
one patient with chronic CSC and one control; calcium channel blockers, by four patients
with acute CSC and one patient with chronic CSC; diuretics, by six patients with acute
CSC, five with chronic CSC, and one control. Finally, sartans were used by one patient with
acute CSC and two patients with chronic CSC. Three patients with acute CSC did not use
any antihypertensive treatment.
Table 1. Demographic and clinical characteristics of patients with acute and chronic central serous
chorioretinopathy as well as controls.




(n = 20) p Value
Male sex, n (%) 24 (80.0) 25 (83.3) 11 (55.0) 0.056 1
Age, y 44.5 (6.1) 42.7 (9.9) 39.2 (7.4) 0.078 2
Smoking (current, former), n (%) 8 (26.7) 7 (23.3) 7 (35.0) 0.658 3
Hypertension, n (%) 6 (20.0) 11 (36.7) 4 (20.0) 0.26 4
Hashimoto thyroiditis, n (%) 2 (6) 1 (3) 0 (0) 0.781
Helicobacter pylori infection, n (%) 6 (20) 0 (0) 0 (0) 0.007
Gout, n (%) 2 (6) 1 (3) 0 (0) 0.781
Ischemic heart disease, n (%) 1 (3) 1 (3) 0 (0) 1.000
1 X2(2) = 5.778; 2 F(2.77) = 2.639; 3 X2(2) = 0.836; 4 X2(2) = 2.690. Data were expressed as mean and standard
deviation where the analysis of variance was used for comparisons unless specified as number (percentage) using
the Pearson χ2 test or the Fisher–Freeman–Halton test as appropriate. A p value of less than 0.05 was considered
significant. Abbreviations: CSC, central serous chorioretinopathy.
No significant differences were observed in the levels of the studied parameters
between patients using at least one antihypertensive drug and those not receiving any anti-
hypertensive medication: PEDF (Me = 94.99, Q1 = 60.99, Q3 = 198.66 and Me = 82.90,
Q1 = 47.91, Q3 = 171.66, respectively, p = 0.508), FGF-basic (Me = 49.97, Q1 = 48.54,
Q3 = 51.37 and Me = 48.54, Q1 = 46.60, Q3 = 51.36, respectively, p = 0.234), endostatin
(Me = 20,098, Q1 = 16,908, Q3 = 22,640 and Me = 17,684, Q1 = 14,759, Q3 = 19,784, re-
spectively, p = 0.05), FGF-acidic (Me = 129.91, Q1 = 125.39, Q3 = 134.43 and Me = 125.39,
Q1 = 118.58, Q3 = 129.91, respectively, p = 0.067), PDGF-AA Me = 177.81, Q1 = 114.33,
Q3 = 256.46 and Me = 191.2, Q1 = 137.72, Q3 = 252.15, respectively, p = 0.557), PlGF
(Me = 3.24, Q1 = 2.9, Q3 = 4.48 and Me = 3.41, Q1 = 2.9, Q3 = 3.94, respectively, p = 0.931),
VEGF-D (Me = 79.41, Q1 = 75.32, Q3 = 86.28 and Me = 78.05, Q1 = 72.61, Q3 = 83.52,
respectively, p = 0.182), thrombospondin-2 (Me = 5534, Q1 = 4455, Q3 = 6725 and Me = 5321,
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Q1 = 4113, Q3 = 6642, respectively, p = 0.553), angiopoetin-1 (Me = 2356, Q1 = 1129, Q3 = 3760
and Me = 2926, Q1 = 1819, Q3 = 3958, respectively, p = 0.224), and VEGF (Me = 12.5,
Q1 = 5.2, Q3 = 20.5 and Me = 9.8, Q1 = 6.8, Q3 = 16.8, respectively, p = 0.968).
The baseline ophthalmological characteristics of patients and controls are presented
in Table 2. The groups differed significantly in terms of best-corrected visual acuity and
mean CT (Table 2).
Table 2. Ophthalmological characteristics of patients with acute and chronic central serous chori-
oretinopathy as well as controls.




(n = 20) p Value
CT, µm 406.1 (88.1) 421.5 (85.3) 317.4 (61.4) <0.001 1
Affected eye, n (%)
Right 10 (33.3) 14 (46.7) -
0.225 2Left 12 (40) 13 (43.3) -
Both 8 (26.7) 3 (10.0) -
BCVA(logMAR), n (%) 0.3< * ≤0.0 23 (76.7) 20 (66.7) 20 (100.0) 0.017 31.0≤ * ≤0.3 7 (23.3) 10 (33.3) 0
* BCVA score. 1 F(2.76) = 10.770; 2 X2(2) = 2.979; 3 X2(2) = 8.092. Data were expressed as mean and standard
deviation where the analysis of variance was used for comparisons unless specified as number (percentage)
using the Pearson χ2 test or the Fisher–Freeman–Halton test as appropriate. A p value of less than 0.05 was
considered significant. Abbreviations: BCVA, best corrected visual acuity; CSC, central serous chorioretinopathy;
CT, choroidal thickness.
At the time of data collection, all patients were treatment naive. Different treatment
modalities were applied after plasma samples were collected.
Data on the plasma levels of angiogenic factors in patients with acute and chronic
CSC as well as controls are shown in Table 3.
Table 3. Plasma levels of angiogenic factors in patients with acute and chronic central serous chorioretinopathy as well as
controls.




(n = 20) p Value
PEDF 94.99 (47.91–200.92) 82.89 (45.73–155.99) 74.12 (54.45–159.35) 0.80 1
FGF-basic 48.97 (2.74) 48.97 (4.71) 50.49 (3.11) 0.28 2
Endostatin 18,009.97 (4466.25) 18,241.17 (4524.54) 16,854.20 (3182.28) 0.49 3
FGF-acid 127.40 (7.92) 125.20 (8.11) 126.08 (8.20) 0.58 4
PDGF-AA 179.04 (87.66) 200.23 (143.25) 265.19 (97.72) 0.03 5
PlGF 3.40 (0.76) 3.44 (0.91) 3.99 (0.96) 0.045 6
VEGF-D 78.62 (5.88) 76.93 (9.66) 77.94 (6.99) 0.70 7
Trombospondin-2 4661.00 (4070.00–6002.00) 5478.00 (5420.00–6933.00) 5898.00 (4750.00–6857.00) 0.07 8
Angiopoietin-1 2894.00 (1722.00–3760.00) 2373.00 (1321.00–2943.00) 3982.00 (2411.00–5617.00) 0.01 9
VEGF 8.80 (6.00-14.40) 9.40 (6.60-13.10) 14.50 (8.60-23.00) 0.07 10
1 X2(2) = 0.447; 2 F(2.77) = 1.275; 3 F(2.77) = 0.707; 4 F(2.76) = 0.553; 5 F(2.77) = 3.558; 6 F(2.77) = 3.230; 7 F(2.77) = 0.359; 8 X2(2) = 5.248;
9 X2(2) = 9.656; 10 X2(2) = 5.091. Data are shown as mean and standard deviation where the analysis of variance was used for comparisons
or as median (interquartile range) using the Kruskal–Wallis test for comparison. A p value of less than 0.05 was considered significant.
Abbreviations: CSC, central serous chorioretinopathy; FGF, fibroblast growth factor; PEDF, pigment epithelium–derived factor; PDGF,
platelet-derived growth factor; PlGF, placental growth factor; VEGF, vascular endothelial growth factor.
Intergroup comparisons of the plasma levels of the 10 measured angiogenic factors
revealed significant differences between the study groups for angiopoietin-1, PlGF, and
PDGF-AA (Figure 1a–c). There were no differences in the levels of the remaining antiangio-
genic factors among the three groups (p > 0.05).
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Figure 1. Box-and-whisker plot of: (a) plasma angiopoietin-1 (p = 0.01; X2(2) = 9.656); (b) placental
growth factor (PlGF; p = 0.045; F(2.77) = 3.230); and (c) plasma pigment epithelium–derived factor
(PDGF-AA; p = 0.03; F(2.77) = 3.558) levels in patients with acute central serous chorioretinopathy,
patients with chronic central serous chorioretinopathy and controls. The line inside the box represents
the median; the lower and upper sides of the box represent the lower and upper quartiles, respectively.
Whiskers represent cases distant up to 1.5 of interquartile range (IQR) from the respective quartile;
circles, cases distant from 1.5 to 3 IQRs. p values were estimated using the analysis of variance for
normally distributed variables and the Kruskal–Wallis test otherwise.
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Subsequent pairwise comparisons showed that in patients with acute CSC (n = 30),
plasma PDGF-AA levels were significantly lower than in the controls (n = 20) (Figure 2),
whereas in patients with chronic CSC (n = 30), angiopoietin-1 levels were significantly
lower than in the controls (n = 20) (Figure 3).
Figure 2. Box-and-whisker plot of plasma pigment epithelium–derived factor (PDGF-AA) levels in
patients with acute central serous chorioretinopathy and controls (p = 0.002; t(48) = 3.252). The line
inside the box represents the median; the lower and upper sides of the box represent the lower and
upper quartiles, respectively. Whiskers represent cases distant up to 1.5 of interquartile range (IQR)
from the respective quartile; circles, cases distant from 1.5 to 3 IQRs. p values were estimated using
the analysis of variance post-hoc Bonferroni test.
Figure 3. Box-and-whisker plot of plasma angiopoietin-1 levels in patients with chronic central
serous chorioretinopathy and controls (p = 0.007; X2(2) = 9.656; post hoc test statistics = 20.3). The
line inside the box represents the median; the lower and upper sides of the box represent the lower
and upper quartiles, respectively. Whiskers represent cases distant up to 1.5 of interquartile range
(IQR) from the respective quartile; circles, cases distant from 1.5 to 3 IQRs. p values were estimated
using the post-hoc pairwise comparison for the Kruskal–Wallis test with Bonferroni correction.
Additionally, we performed an analysis for the whole CSC group (patients with both
chronic and acute form, n = 60) vs. controls (n = 20). Plasma VEGF, PDGF-AA, and PlGF
levels in patients with acute or chronic CSC (n = 60) were significantly lower than in the
controls (Figure 4a–c).
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Figure 4. Box-and-whisker plot of: (a) plasma vascular endothelial growth factor (VEGF; p = 0.024);
(b) plasma placental growth factor (PlGF; p = 0.013; t(48)= −2.551); (c) platelet-derived growth factor
AA (PDGF-AA; p = 0.012; t(48) = −2.577) levels in all patients with central serous chorioretinopathy
(acute and chronic) and controls. The line inside the box represents the median; the lower and upper
sides of the box represent the lower and upper quartiles, respectively. Whiskers represent cases
distant up to 1.5 of interquartile range (IQR) from the respective quartile; circles, cases distant from
1.5 to 3 IQRs. p values were estimated using the t-test for normally distributed variables and the
Mann–Whitney test otherwise.
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The analysis of the correlation between mean CT and VEGF for the whole CSC cohort
(n = 60) revealed an inverse correlation, which was particularly prominent after exclusion
of a single outlier in VEGF measurement (>50 pg/mL) (Figure 5a). Further analysis proved
that this correlation was true for patients with chronic CSC (Figure 5b), but was not
observed in the acute-CSC group (rho = 0.07, p = 0.721).
Figure 5. Scatterplots showing the correlations between: (a) mean choroidal thickness (CT) and
vascular endothelial growth factor (VEGF) levels in patients with acute and chronic central serous
chorioretinopathy (rho = −0.27, p = 0.044); (b) mean CT and VEGF levels in patients with chronic
central serous chorioretinopathy (rho = −0.48, p = 0.009). The strength of the relationship between
the variables was estimated using the Spearman rank correlation coefficient rho. The shape of the
relationship was presented using the loess curve.
4. Discussion
Choroidal vasculature plays a crucial role in retinal homeostasis and preservation of
good vision and vision-related Quality of Life [27]. Importantly, the key pathophysiologic
mechanism in CSC is associated with the presence of abnormally thick choroid, hyperper-
meable, and dilated choroidal vessels with or without RPE abnormalities overlying the
pachyvessels [7]. Dysregulation in angiogenesis and arteriogenesis has been suggested as
an underlying mechanism for the development of some chorioretinal diseases [3,19].
Angiogenesis is a highly controlled process involving the formation of new blood
vessels from a preexisting vascular bed and depends on an intricate balance of both proan-
giogenic and antiangiogenic factors. On the other hand, arteriogenesis refers to anatomic
transformation of preexisting arterioles, with an increase in the lumen area and wall
thickness, due to a thick muscular layer and development of viscoelastic and vasomo-
tor capacities [25]. The two processes differ in several aspects, with the most important
being that angiogenesis depends on hypoxia and arteriogenesis on inflammation [25].
Based on these facts, it may be suspected that there is a relationship between the patho-
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genesis of pachychoroid diseases, especially CSC, and the levels of angiogenic factors in
human blood.
To the best of our knowledge, this is the first study that assessed the plasma levels of
angiogenic factors such as angiopoietin-1, endostatin, FGF-acidic, FGF-basic, PlGF, PDGF-
AA, thrombospondin-2, VEGF, VEGF-D, and PEDF in patients with CSC in comparison
with heathy individuals. We noted differences in the plasma levels of angiopoietin-1, PlGF,
and PDGF-AA between patients with acute and chronic CSC as well as the controls. The
levels of PDGF-AA were downregulated only in acute CSC, whereas those of angiopoietin-1
only in chronic CSC, compared with the controls.
It has been shown that angiopoietin-1 is essential for vessel stabilization and quies-
cence in adults [28]. In this context, Lee et al. [29] found that the interendothelial junctional
protein reduced recruitment and infiltration of macrophages from the Bruch’s membrane,
thus preventing CNV formation and consecutive vascular leakage. Interestingly, a dysreg-
ulated interaction between the RPE and infiltrated macrophages results in upregulation
of angiogenesis and leads to choroidal abnormalities in chronic CSC [30]. Terao et al. [30]
reported that inflammation, accompanied by macrophage infiltration, into the choroid
and retina may cause CSC progression from the acute to chronic form. Angiopoietin-1 is
also known to support endothelial cell stabilization by activating the Tie-2 receptor and to
decrease vascular leakage by increasing the level of the interendothelial cell junction pro-
teins [29]. Previous studies revealed that angiopoietin-1 prevents the VEGF-A–mediated
junction disruption [21]; however, a recent report indicated that it may directly stabilize
vascular endothelial cadherin and zonula occludens-1 by regulating the RhoA-specific
guanine nucleotide exchange factor Syx [31]. Noteworthy, administration of angiopoietin-1
into the vitreous body upregulates the expression of vascular endothelial cadherin and
zonula occludens-1, the key factors of endothelial cell-to-cell junctions preserving vascular
integrity [28,32]. We hypothesized that the deficiency of angiopoietin-1 demonstrated in
our study may result in dissociation of endothelial tight junctions in the choriocapillaris and
choroid, leading to chronic vascular dysfunction associated with the prolonged presence of
the serous retinal detachment and/or fluid under the RPE in the course of chronic CSC.
Schubert et al. [33] postulated that structural and molecular changes in the choriocap-
illaris and choroid in CSC can alter the microenvironment of the RPE. This, in turn, can
affect RPE barrier capabilities and its transport [33]. The endothelial cells of the choriocap-
illaris are fenestrated; therefore, they have higher permeability than the nonfenestrated
retinal capillaries. This may suggest that even in physiological conditions, the RPE is
regularly exposed to plasma filtrate [33]. In our study, the plasma concentrations of PlGF
and PDGF-AA were downregulated in patients with CSC compared with the controls.
Placental growth factor is a multifunctional cytokine affecting diverse cellular activities [34].
Its pleiotropic effects on junction stabilization, survival, proliferation, and metabolism as
well activation effects on vascular cells (i.e., pericytes and smooth muscle cells, endothelial
cells) were reported [34]. There is an increasing body of evidence showing that lowering
or elevating PlGF expression may lead to various diseases [34]. Moreover, PlGF increases
the expression of some angiogenic factors such as VEGF, PDGF-B, and FGF-2 [29], which
stimulate angiogenesis through proliferation of endothelial cells and arteriogenesis through
smooth muscles [35].
Platelet-derived growth factor stimulates both arteriogenesis and angiogenesis [25].
Tumor growth factor-β produced by different cells is a chemoattractant for monocytes. It
also stimulates the expression of PDGF by these cells during arteriogenesis [35], which
may be involved in the development of CNV in chronic CSC [36]. The deficiency of PDGF
in acute CSC may explain the absence of CNV, but this hypothesis merits further research.
Saito et al. [37] confirmed that PDGF-AA was crucial for retina regeneration within the first
hours after injury; therefore, its deficiency may play a role in the acute form of CSC.
In our study, the VEGF was significantly downregulated in patients with CSC (both
acute and chronic) compared with the controls. Only a few studies assessed angiogenic
factors in plasma and aqueous humor (AH) of patients with CSC. Lim et al. [38] did not
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show any differences in plasma and AH levels of VEGF in CSC compared with the controls.
However, the study was limited by a small group of patients, mostly with acute CSC, which
precluded a definitive conclusion. Shin et al. [39] reported similar, but very low, AH levels
of VEGF in patients with CSC and the controls, but PDGF levels were lower in CSC.
Downregulated plasma VEGF levels in CSC compared with the healthy individu-
als observed in our study may partially explain an unsatisfactory effect of intravitreal
anti-VEGF treatment in patients with CSC [2,40]. Even though CSC is described as a
vascular disorder (pachychoroid), the primary exudative component leading to a macular
detachment is considered to be nonvasogenic, which means that it does not result directly
from the proliferation of choroidal vessels [8,41]. This is an essential difference between
CSC and other conditions presenting with serous macular detachment and CNV such as
nAMD [8,41,42].
The fact that chronic CSC can be associated with the presence of CNV [16,17] does
not contradict the results of our study, which revealed lower plasma VEGF levels in CSC
patients compared with the controls. This is in line with the studies by Spaide et al. [36] and
Sacconi et al. [43]. They hypothesized that CNV in CSC occurs as a result of proliferation
of new vessels during arteriogenesis, which is characterized by dilation of the existing
vascular channels and is independent of VEGF (unlike angiogenesis, which is highly VEGF
dependent) [44]. On the other hand, VEGF alters the junctional integrity, downregulates
the expression of occludin and zonula occludens-1 [45–48], which results in increased
permeability and angiogenesis [15,49]. Downregulated VEGF levels observed in our study
may suggest that the mechanism of vascular hyperpermeability in CSC is similar to that
of CNV in VEGF independent CSC and may result from altered flow in dilated choroidal
vessels (pachyvessels) [7]. The increased flow leads to endothelial cell proliferation, with
luminar expansion and release of platelet endothelial cell adhesion molecule-1, monocyte
chemoattractant protein-1, intracellular adhesion molecule-1, and vascular cell adhesion
molecule-1 [50]. As a result, increased endothelial permeability, as indicated by the leakage
of plasma proteins, erythrocytes, and platelets into the vascular wall and the adherence of
monocytes to the endothelium, was observed, along with the recruitment of circulating
monocytes and resident macrophages [51]. This, in turn, promotes arteriogenesis by the
ability of monocytes and macrophages to secrete metalloproteinases, chemokines, and
growth factors [25,52].
We hypothesized that the impaired function of RPE cells in CSC, a major source of
ocular proangiogenic proteins, may result in decreased intraocular levels of VEGF, but it
does not fully explain the downregulation of the other analyzed proangiogenic factors in
the eyes, especially in plasma. This issue merits further investigation.
In the current study, we did not find differences in the levels of antiangiogenic proteins,
trombospondin-2, and endostatin between patients with CSC and the controls. It is well
known that antihypertensive drugs affect angiogenesis [53,54]. However, in our study, we
did not observe any differences in the levels of proangiogenic and antiangiogenic factors
between patients using at least one antihypertensive drug and those not receiving any
medication. This finding requires further research.
In our study, an inverse correlation between mean CT and VEGF was observed
in chronic CSC. It was shown that a decrease in VEGF levels in intraocular fluids as a
result of intravitreal anti-VEGF therapy leads to a decrease in CT in patients with diabetic
retinopathy [55]. Furthermore, some studies reported a decrease in CT in patients with
acute CSC after anti-VEGF treatment [56]. These data suggest that certain levels of VEGF
are necessary to maintain choroidal stability and function, which is also in line with our
results. Nevertheless, this is an interesting phenomenon that definitely deserves a more
substantial discussion and more thorough research.
Our study was limited by the fact that it was performed at a single time point and
only plasma, and not AH, samples were investigated. Moreover, there were possible
confounding factors affecting the levels of angiogenic factors such as concomitant anti-
hypertensive treatment. Finally, during blood sample collection, we did not record the
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stage of the menstruation cycle in women at reproductive age, while menstruation cycle
is known to affect angiogenic markers. Although the lack of AH assessment may be an
important limitation, the significant differences in the plasma levels of angiogenic factors
are an interesting finding, indicating that CSC might be a systemic disease.
5. Conclusions
Downregulated angiopoietin-1, VEGF, PDGF-AA, and PlGF levels observed in our
study may highlight the previously unknown role of the imbalanced levels of proan-
giogenic and antiangiogenic factors, which affect choroidal hyperpermeability and exert
profound changes in venular structure and function, thus possibly contributing to the
pathogenesis of CSC. Lower plasma levels of VEGF in patients with CSC may support
the hypothesis that CNV occurs in these patients as a result of arteriogenesis, which is
less VEGF-dependent than angiogenesis. Moreover, our findings may support the search
for new therapeutic strategies in CSC. Nevertheless, the underlying mechanisms that
contribute to this condition remain largely unknown and require further studies.
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cytokine levels in acute and chronic central serous chorioretinopathy. Acta Ophthalmol. 2020. [CrossRef] [PubMed]
16. Shiragami, C.; Takasago, Y.; Osaka, R.; Kobayashi, M.; Ono, A.; Yamashita, A.; Hirooka, K. Clinical Features of Central Serous
Chorioretinopathy With Type 1 Choroidal Neovascularization. Am. J. Ophthalmol. 2018, 193, 80–86. [CrossRef]
17. Mrejen, S.; Balaratnasingam, C.; Kaden, T.R.; Bottini, A.; Dansingani, K.; Bhavsar, K.V.; Yannuzzi, N.A.; Patel, S.; Chen, K.C.;
Yu, S.; et al. Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy. Ophthalmology
2019, 126, 576–588. [CrossRef]
18. Van Bergen, T.; Etienne, I.; Cunningham, F.; Moons, L.; Schlingemann, R.O.; Feyen, J.H.M.; Stitt, A.W. The role of placental growth
factor (PlGF) and its receptor system in retinal vascular diseases. Prog. Retin. Eye Res. 2019, 69, 116–136. [CrossRef]
19. Muether, P.S.; Neuhann, I.; Buhl, C.; Hermann, M.M.; Kirchhof, B.; Fauser, S. Intraocular growth factors and cytokines in patients
with dry and neovascular age-related macular degeneration. Retina Phila. Pa 2013, 33, 1809–1814. [CrossRef] [PubMed]
20. Siedlecki, J.; Wertheimer, C.; Wolf, A.; Liegl, R.; Priglinger, C.; Priglinger, S.; Eibl-Lindner, K. Combined VEGF and PDGF
inhibition for neovascular AMD: Anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro. Graefes
Arch. Clin. Exp. Ophthalmol. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 2017, 255, 963–972. [CrossRef] [PubMed]
21. Gavard, J.; Patel, V.; Gutkind, J.S. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through
mDia. Dev. Cell 2008, 14, 25–36. [CrossRef]
22. Nagy, J.A.; Benjamin, L.; Zeng, H.; Dvorak, A.M.; Dvorak, H.F. Vascular permeability, vascular hyperpermeability and angiogene-
sis. Angiogenesis 2008, 11, 109–119. [CrossRef]
23. Farnoodian, M.; Wang, S.; Dietz, J.; Nickells, R.W.; Sorenson, C.M.; Sheibani, N. Negative regulators of angiogenesis: Important
targets for treatment of exudative AMD. Clin. Sci. Lond. Engl. 1979 2017, 131, 1763–1780. [CrossRef] [PubMed]
24. Kuwano, M.; Fukushi, J.; Okamoto, M.; Nishie, A.; Goto, H.; Ishibashi, T.; Ono, M. Angiogenesis factors. Intern. Med. Tokyo Jpn.
2001, 40, 565–572. [CrossRef] [PubMed]
25. Rizzi, A.; Benagiano, V.; Ribatti, D. Angiogenesis versus arteriogenesis. Rom. J. Morphol. Embryol. Rev. Roum. Morphol. Embryol.
2017, 58, 15–19.
26. Branchini, L.A.; Adhi, M.; Regatieri, C.V.; Nandakumar, N.; Liu, J.J.; Laver, N.; Fujimoto, J.G.; Duker, J.S. Analysis of choroidal
morphologic features and vasculature in healthy eyes using spectral-domain optical coherence tomography. Ophthalmology 2013,
120, 1901–1908. [CrossRef] [PubMed]
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